Evidence map›Paper›PMID 28596526›Full record

ArticleScientific reports2017

Mechanistic roles of microRNAs in hepatocarcinogenesis: A study of thioacetamide with multiple doses and time-points of rats.

Harsh Dweep, Yuji Morikawa, Binsheng Gong, Jian Yan, Zhichao Liu, Tao Chen, Halil Bisgin, Wen Zou, Huixiao Hong, Tieliu Shi and 5 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Functional Annotation of MicroRNAs Using Existing Resources.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 3 countries.

Harsh DweepDivision of Bioinformatics and Biostatistics, National Center for Toxicological Research, FDA, Jefferson, AR, 72079, USA.
Yuji MorikawaInformatics & Structure-based Drug Discovery, Discovery Research Laboratories for Innovative Frontier Medicines, Shionogi & Co. Ltd., Toyonaka, Osaka, Japan.
Binsheng GongDivision of Bioinformatics and Biostatistics, National Center for Toxicological Research, FDA, Jefferson, AR, 72079, USA.
Jian YanDivision of Genetic and Molecular Toxicology, National Center for Toxicological Research, FDA, Jefferson, AR, 72079, USA.
Zhichao LiuDivision of Bioinformatics and Biostatistics, National Center for Toxicological Research, FDA, Jefferson, AR, 72079, USA.
Tao ChenDivision of Genetic and Molecular Toxicology, National Center for Toxicological Research, FDA, Jefferson, AR, 72079, USA.
Halil BisginDepartment of Computer Science, Engineering, and Physics, University of Michigan-Flint, 303 East Kearsley Street, Flint, MI, 48502, USA.
Wen ZouDivision of Bioinformatics and Biostatistics, National Center for Toxicological Research, FDA, Jefferson, AR, 72079, USA.
Huixiao HongDivision of Bioinformatics and Biostatistics, National Center for Toxicological Research, FDA, Jefferson, AR, 72079, USA.
Tieliu ShiCenter for Bioinformatics and Computational Biology, and the Institute of Biomedical Sciences, College of Life Science, East China Normal University, Shanghai, China.
Ping GongEnvironmental Laboratory, U.S. Army Engineer Research and Development Center, 3909 Halls Ferry Road, Vicksburg, MS, 39180, USA.
Christina CastroUniversity of North Carolina at Charlotte, 9201 University City Blvd, Charlotte, NC, 28223, USA.
Takeki UeharaGlobal Project Management Department, Shionogi & Co., Ltd., Osaka, Japan. takeki.uehara@shionogi.co.jp.
Yuping WangDivision of Bioinformatics and Biostatistics, National Center for Toxicological Research, FDA, Jefferson, AR, 72079, USA. Yuping.wang@fda.hhs.gov.
Weida TongDivision of Bioinformatics and Biostatistics, National Center for Toxicological Research, FDA, Jefferson, AR, 72079, USA. Weida.tong@fda.hhs.gov.
National Center for Toxicological Research · USEast China Normal University · CNFutaba (Japan) · JPShionogi (Japan) · JPUnited States Army · USUniversity of Michigan–Flint · USUniversity of North Carolina at Charlotte · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Environmental chemicals exposure is one of the primary factors for liver toxicity and hepatocarcinoma. Thioacetamide (TAA) is a well-known hepatotoxicant and could be a liver carcinogen in humans. The discovery of early and sensitive microRNA (miRNA) biomarkers in liver injury and tumor progression could improve cancer diagnosis, prognosis, and management. To study this, we performed next generation sequencing of the livers of Sprague-Dawley rats treated with TAA at three doses (4.5, 15 and 45 mg/kg) and four time points (3-, 7-, 14- and 28-days). Overall, 330 unique differentially expressed miRNAs (DEMs) were identified in the entire TAA-treatment course. Of these, 129 DEMs were found significantly enriched for the "liver cancer" annotation. These results were further complemented by pathway analysis (Molecular Mechanisms of Cancer, p53-, TGF-β-, MAPK- and Wnt-signaling). Two miRNAs (rno-miR-34a-5p and rno-miR-455-3p) out of 48 overlapping DEMs were identified to be early and sensitive biomarkers for TAA-induced hepatocarcinogenicity. We have shown significant regulatory associations between DEMs and TAA-induced liver carcinogenesis at an earlier stage than histopathological features. Most importantly, miR-34a-5p is the most suitable early and sensitive biomarker for TAA-induced hepatocarcinogenesis due to its consistent elevation during the entire treatment course.

Indexed as

AnimalsCarcinogenesisLiverLiver NeoplasmsMaleMAP Kinase Signaling SystemMicroRNAsRatsRats, Sprague-DawleyThioacetamideWnt Signaling PathwayMicroRNAsThioacetamide

Identifiers

PMID28596526
PMCPMC5465221
OpenAlexW2621277660

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.